Cytek Biosciences, Inc. (CTKB)
| Market Cap | 565.62M +18.1% |
| Revenue (ttm) | 201.49M +0.5% |
| Net Income | -66.54M |
| EPS | -0.52 |
| Shares Out | 128.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 577,676 |
| Open | 4.250 |
| Previous Close | 4.260 |
| Day's Range | 4.250 - 4.550 |
| 52-Week Range | 2.370 - 6.180 |
| Beta | 1.28 |
| Analysts | Hold |
| Price Target | 5.63 (+27.96%) |
| Earnings Date | May 7, 2026 |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek mu... [Read more]
Financial Performance
In 2025, Cytek Biosciences's revenue was $201.49 million, an increase of 0.52% compared to the previous year's $200.45 million. Losses were -$66.54 million, 1005.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CTKB stock is "Hold." The 12-month stock price target is $5.63, which is an increase of 27.96% from the latest price.
News
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter...
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek's manufacturing capacity and regional service.
Cytek Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Revenue grew 1% to $201.5M in 2025, outpacing a declining market and expanding global reach. Product innovation, especially Aurora Evo, and recurring revenue from services and reagents drive growth. APAC and clinical markets are key priorities for 2026.
Cytek Biosciences Earnings Call Transcript: Q4 2025
Record Q4 revenue and a return to growth in H2 2025 were driven by strong performance in APAC, EMEA, and recurring revenue streams. Despite higher operating expenses and non-cash tax write-offs, liquidity remains strong, and 2026 guidance anticipates continued growth and positive adjusted EBITDA.
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and ...
Cytek Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
A leading cell analysis company reported $201 million in 2024 revenue, driven by market share gains, product innovation, and global expansion. Growth is expected to accelerate through 2026, supported by new product launches, increased reagent sales, and a balanced capital allocation strategy.
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Company to present at the 44th Annual JP Morgan Healthcare Conference Company to present at the 44th Annual JP Morgan Healthcare Conference
Cytek Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference
Double-digit growth continues in most segments, with Asia-Pacific and US markets strong and Europe stabilizing. Aurora Evo adoption is accelerating, reagent revenue is outpacing the market, and comprehensive solutions drive customer loyalty. EMEA challenges are seen as cyclical, with recovery expected.
TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026
FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME's 2026 list of America's Growth Leaders.
Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek ® Muse ® Micro cell analyzer has been named Drug Discovery Solution of the Year...
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following...
Cytek Biosciences Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 2% year-over-year to $52.3M, led by APAC and recurring revenue, while EMEA declined sharply. Adjusted EBITDA fell to $2.5M, and net loss was $5.5M. Full-year guidance of $196–$205M was reaffirmed, with strong APAC and recurring revenue momentum expected.
Cytek Biosciences Reports Third Quarter 2025 Financial Results
FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. ...
Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025
FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 ...
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Na...
Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q's Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announces multiple strategic technology partnerships to advance the Cell...
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc. (...
Cytek Biosciences Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Despite market headwinds, FSP instrument volumes grew 3% and recurring revenues rose 18% year-over-year. Aurora Evo launched with pharma-focused features, while Asia-Pacific and reagent businesses drive growth. High incremental margins position the company for strong profitability as the market recovers.
Cytek Biosciences Transcript: UBS Precision Medicine Frontiers Summit
Panelists highlighted breakthroughs in proteomics and flow cytometry, enabling new research and clinical applications. Strategic focus on technology validation, flexible sales, and AI-driven innovation supports growth despite market challenges.
Cytek Biosciences Earnings Call Transcript: Q2 2025
Q2 2025 revenue declined 2.2% year-over-year to $45.6M, with strong recurring revenue growth offsetting product weakness in EMEA and APAC. Full-year guidance narrowed to $196M–$205M, and new product launches and expanding recurring revenue streams position the company for long-term growth.
Cytek Biosciences Reports Second Quarter 2025 Financial Results
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...
Cytek Biosciences Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
Service and Asia Pacific businesses are driving growth, while recurring revenue is set to increase significantly. Operational efficiency, regional manufacturing, and the expanding Cytek Cloud platform support strong margins and customer retention. Recent product launches and positive cash flow position the company for continued outperformance.